drugset / Trial / NCT00377780
Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is an open phase II study evaluating the efficacy and safety of the non pegylated liposomal doxorubicin (Myocet®), trastuzumab (Herceptin®), and docetaxel (Taxotere®) combination as first-line treatment of patients with metastatic HER2/neu positive breast cancer.
Timeline
- Start
- 2006-08
- Primary completion
- 2015-08
- Completion
- 2015-08
Outcome
Outcome not reported
Stopped: “wothdrawal of sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |